Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
- PMID: 35655707
- PMCID: PMC9154809
- DOI: 10.1080/2162402X.2022.2077898
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Abstract
The past decades witnessed the clinical employment of targeted therapies including but not limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic signals. TKIs can be categorized into (i) agents that directly target cancer cells, (ii) normalize angiogenesis or (iii) affect cells of the hematologic lineage. However, a clear distinction of TKIs based on this definition is limited by the fact that many TKIs designed to inhibit cancer cells have also effects on immune cells that are being discovered. Additionally, TKIs originally designed to target hematological cancers exhibit bioactivities on healthy cells of the same hematological lineage. TKIs have been described to improve immune recognition and cancer immunosurveillance, providing the scientific basis to combine TKIs with immunotherapy. Indeed, combination of TKIs with immunotherapy showed synergistic effects in preclinical models and clinical trials and some combinations of TKIs normalizing angiogenesis with immune checkpoint blocking antibodies have already been approved by the FDA for cancer therapy. However, the identification of appropriate drug combinations as well as optimal dosing and scheduling needs to be improved in order to obtain tangible progress in cancer care. This Trial Watch summarizes active clinical trials combining TKIs with various immunotherapeutic strategies to treat cancer patients.
Keywords: Immunotherapy; checkpoint blockade; lung cancer; personalized medicine; targeted therapy.
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Conflict of interest statement
OK is a scientific co-founder of Samsara. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sanofi, Sotio, Tollys, Vascage and Vasculox/Tioma. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. MCM is named as an inventor on a patent describing a method for the diagnosis and prognosis of breast cancer.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9154809/bin/KONI_A_2077898_F0001_OC.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9154809/bin/KONI_A_2077898_F0002_OC.gif)
Similar articles
-
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.J Hematol Oncol. 2019 Mar 12;12(1):27. doi: 10.1186/s13045-019-0718-5. J Hematol Oncol. 2019. PMID: 30866992 Free PMC article. Review.
-
Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?J Oncol Pharm Pract. 2021 Jun;27(4):930-938. doi: 10.1177/1078155220984235. Epub 2021 Jan 6. J Oncol Pharm Pract. 2021. PMID: 33406979 Review.
-
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.Trends Mol Med. 2010 Apr;16(4):184-92. doi: 10.1016/j.molmed.2010.02.001. Epub 2010 Mar 19. Trends Mol Med. 2010. PMID: 20304705 Review.
-
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11579-11586. doi: 10.1073/pnas.1816012116. Epub 2019 May 10. Proc Natl Acad Sci U S A. 2019. PMID: 31076554 Free PMC article.
-
Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.Cancer J. 2016 May-Jun;22(3):182-9. doi: 10.1097/PPO.0000000000000192. Cancer J. 2016. PMID: 27341596 Review.
Cited by
-
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.Oncoimmunology. 2024 Mar 3;13(1):2321648. doi: 10.1080/2162402X.2024.2321648. eCollection 2024. Oncoimmunology. 2024. PMID: 38445082 Free PMC article. Review.
-
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.Commun Chem. 2024 Jan 3;7(1):3. doi: 10.1038/s42004-023-01084-0. Commun Chem. 2024. PMID: 38172256 Free PMC article.
-
Molecular determinants of immunogenic cell death elicited by radiation therapy.Immunol Rev. 2024 Jan;321(1):20-32. doi: 10.1111/imr.13271. Epub 2023 Sep 7. Immunol Rev. 2024. PMID: 37679959 Free PMC article. Review.
-
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.Mol Cancer. 2023 Jul 29;22(1):121. doi: 10.1186/s12943-023-01826-7. Mol Cancer. 2023. PMID: 37516849 Free PMC article. Review.
-
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.Front Oncol. 2023 Jul 10;13:1199105. doi: 10.3389/fonc.2023.1199105. eCollection 2023. Front Oncol. 2023. PMID: 37492478 Free PMC article. Review.
References
-
- Yamazaki T, Wennerberg E, Hensler M, Buque A, Kraynak J, Fucikova J, Zhou XK, Sveinbjornsson B, Rekdal O, Demaria S, et al. LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. Oncoimmunology. 2021;10(1):1962592. doi:10.1080/2162402X.2021.1962592. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous